Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 2/20 | 0.33 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.33 |
| ▸ | CDK1 | P06493 | 2/20 | 0.33 |
| ▸ | CDK4 | P11802 | 2/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.33 |
| ▸ | CCND1 | P24385 | 2/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.33 |
| ▸ | CDK2 | P24941 | 2/20 | 0.33 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2308457 | 0.81 | — | — | |
| SCHEMBL19220574 | 0.81 | POLB (0.33) | — | |
| SCHEMBL19558774 | 0.80 | CCNB2 (0.31) | CCNB2CCNE2CDK1CDK4CCNB1 | |
| SCHEMBL13561286 | 0.78 | MEN1 (0.38) | — | |
| SCHEMBL13561294 | 0.78 | ACHE (0.36) | — | |
| SCHEMBL18895693 | 0.77 | MAPT (0.35) | — | |
| SCHEMBL15625395 | 0.75 | AGBL2 (0.33) | CCNB2CCNE2CDK1CDK4CCNB1 | |
| SCHEMBL24608447 | 0.74 | — | — | |
| SCHEMBL12824205 | 0.73 | — | — | |
| SCHEMBL20273003 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024026500-A2 | INHIBITORS OF PDE11A4 AND METHODS OF USING SAME | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20230399319-A1 | Acylsulfamide Compound and Pharmaceutical Use Therefor | JAPAN TOBACCO INC. (JP) | 2023-12-14 | — | — | US | disclosed |
| US-20220396587-A1 | MACROCYCLIC FUSED PYRRAZOLES AS MCL-1 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-12-15 | — | — | US | disclosed |
| US-20200390100-A1 | SUBSTITUTED N-HETEROCYCLYL- AND N-HETEROARYL-TETRAHYDROPYRIMIDINONES AND THE SALTS THEREOF, AND THE USE OF SAME AS HERBICIDAL ACTIVE SUBSTANCES | BAYER AG (DE) | 2020-12-17 | — | — | US | disclosed |
| US-10752611-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10646494-B2 | Heterocycle-substituted tetracyclic compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20170239351-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor | ACERTA PHARMA BV (NL) | 2017-08-24 | — | — | US | disclosed |
| US-9676802-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARM INC (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170079960-A1 | INSULIN SENSITISERS AND METHODS OF TREATMENT | NAIA Metabolic, Inc. | 2017-03-23 | — | — | US | disclosed |
| US-20170057960-A1 | INDOLIN-2-ONE AND 1,3-DIHYDRO-PYRROLO[3,2-c]PYRIDIN-2-ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-03-02 | — | — | US | disclosed |
| US-9181273-B2 | Morpholine-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150025073-A1 | MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2015-01-22 | — | — | US | disclosed |
| US-8828996-B2 | Morpholine-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-09 | — | — | US | disclosed |
| US-20120264749-A1 | MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | CCNB2 755/4885CCNE2 99/4885CDK1 126/4885 |
| US-20200390100-A1 | SUBSTITUTED N-HETEROCYCLYL- AND N-HETEROARYL-TETRAHYDROPYRIMIDINONES AND THE SALTS THEREOF, AND THE USE OF SAME AS HERBICIDAL ACTIVE SUBSTANCES | DDT, NOTUM, AGPS | CCNB2 1739/4885CCNE2 961/4885CDK1 1462/4885 |
| US-10646494-B2 | Heterocycle-substituted tetracyclic compounds and methods of use thereof for the treatment of viral diseases | HAVCR2, HCCS, ZC3HAV1 | CCNB2 763/4885CCNE2 148/4885CDK1 218/4885 |
| US-20220396587-A1 | MACROCYCLIC FUSED PYRRAZOLES AS MCL-1 INHIBITORS | MCL1, BCL2A1, BCL2L1 | CCNB2 295/4885CCNE2 427/4885CDK1 48/4885 |
| US-20170079960-A1 | INSULIN SENSITISERS AND METHODS OF TREATMENT | GPR119, IRS1, SLC2A1 | CCNB2 4800/4885CCNE2 4513/4885CDK1 3688/4885 |
| US-20170057960-A1 | INDOLIN-2-ONE AND 1,3-DIHYDRO-PYRROLO[3,2-c]PYRIDIN-2-ONE DERIVATIVES | TPH1, TPH2, HTR1A | CCNB2 299/4885CCNE2 835/4885CDK1 416/4885 |
| US-20170239351-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor | BTK, JAK1, PDCD1 | CCNB2 1993/4885CCNE2 1436/4885CDK1 303/4885 |
| US-20150025073-A1 | MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, TRPM5, KCNQ1 | CCNB2 4145/4885CCNE2 3930/4885CDK1 3526/4885 |
| US-20230399319-A1 | Acylsulfamide Compound and Pharmaceutical Use Therefor | NLRP3, NLRP1, NOD1 | CCNB2 4764/4885CCNE2 4796/4885CDK1 4372/4885 |
| US-20120264749-A1 | MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, TRPM5, KCNQ1 | CCNB2 4145/4885CCNE2 3930/4885CDK1 3526/4885 |
| US-10752611-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | CCNB2 911/4885CCNE2 123/4885CDK1 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.